Sinecatechins is a prescription medicine indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older, among other approved uses. It is available as ointment for topical use. MedsAcross supplies Sinecatechins for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses.
Source: US FDA prescribing information
The mode of action of Veregen involved in the clearance of genital and perianal warts is unknown. In vitro, sinecatechins had anti-oxidative activity, the clinical significance of this finding is unknown.
Source: US FDA prescribing information
• Veregen is to be applied three times per day to all external genital and perianal warts. • Apply about an 0.5 cm strand of ointment to each wart using the finger(s), dabbing it on to ensure complete coverage and leaving a thin layer of the ointment on the warts. • Veregen is not for ophthalmic, oral, intravaginal, or intra-anal use.
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
Veregen has not been evaluated for the treatment of urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used for the treatment of these conditions. Use of Veregen on open wounds should be avoided. Patients should be advised to avoid exposure of the genital and perianal area to sun/UV-light as Veregen has not been tested under these circumstances. • Veregen should not be used to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease. • Use of Veregen on open wounds should be avoided. • Avoid exposure of Veregen treated areas to sun/UV-light as Veregen has not been tested under these circumstances.
Source: US FDA prescribing information
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In Phase 3 clinical trials, a total of 397 subjects received Veregen three times per day topical application for the treatment of external genital and perianal warts for up to 16 weeks. Serious local adverse events of pain and inflammation were reported in two subjects (0.5%), both women. In clinical trials, the incidence of patients with local adverse events leading to discontinuation or dose interruption (reduction) was 5% (19/397).
Source: US FDA prescribing information
Prior to dispensing to the patient, store refrigerated 2°C to 8°C (36°F to 46°F). After dispensing, store refrigerated or up to 25°C (77°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Sinecatechins, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Veregen 15% ointmentTopical Cold chain | ANI Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 31 October 2006 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Sinecatechins and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Sinecatechins, including Veregen.
Yes. The US FDA first approved Sinecatechins on 31 October 2006, according to Drugs@FDA.
At least one listed presentation of Sinecatechins must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Sinecatechins is classified under ATC code D06BB12 (Sinecatechins).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.